Suthat Rungruanghiranya

"Tobacco dependence remains the leading single cause of preventable global morbidity and mortality, accounting for over 7 million deaths annually among 1.3 billion tobacco users worldwide. An acute global equity gap persists: 80% of all tobacco users reside in Low- and Middle-Income Countries (LMICs), yet population-level access to World Health Organization (WHO) best-practice cessation services stands at only 4% in low-income countries and 11% in middle-income countries, compared to 28% in high- income countries (HICs). While HIC treatment guidelines rely heavily on insurance-covered, high-cost first-line pharmacotherapies such as Varenicline ($400–$500 per course) and combination nicotine replacement therapy (NRT), LMIC populations face a severe economic hurdle where the out-of-pocket cost for a single month of NRT frequently exceeds the cost of continuing to smoke. This presentation evaluates strategies to bridge this global divide by analyzing the neurobiological imperatives of tobacco addiction, comparing clinical treatment guidelines, and introducing high-efficacy, low-cost pharmacotherapy combined with scalable community delivery models. Neurobiological evidence confirms that tobacco dependence is a physiological receptor-driven addiction requiring pharmacotherapy, which quintuples cessation success compared to unassisted quit attempts (~25% vs ~5%). Cytisine—a plant-based partial α4β2 nicotinic receptor agonist costing ~$20–$30 per treatment course—emerges as a transformative solution for LMICs. Clinical evidence from the randomized, double-blind Thai STEP trial (Respirology 2024; n=1,086) demonstrated that a 25-day course of locally manufactured Cytisine achieved non-inferior continuous abstinence rates compared to a 12-week course of Nortriptyline (10% at 12 months) with favorable tolerability. To operationalize these findings in resource-constrained health systems, a three-tiered LMIC master-algorithm is presented: task-shifting initial screening (Ask & Advise) to Community Health Workers, scaling automated mobile mCessation behavioral support, and providing generic Cytisine. Because global tobacco control 's primary challenge is structural rather than scientific, pairing affordable essential medicines with community-based participatory care offers a proven, equitable path toward reducing global tobacco mortality."

Tobacco use remains the leading preventable cause of death across the Asia-Pacific region, yet this area also demonstrates that comprehensive, well-financed, and industry-insulated legislation can effectively reduce smoking prevalence. This summary explores the legislative and governance frameworks essential for robust tobacco control, primarily focusing on the WHO Framework Convention on Tobacco Control (FCTC) and the MPOWER technical package. Effective governmental strategies require simultaneous implementation of multiple measures, including progressive excise taxation, comprehensive smoke-free laws, and standardized packaging with pictorial health warnings. Furthermore, securing earmarked and transparent financing, as exemplified by Thailand's Health Promotion Foundation (ThaiHealth), provides the operational continuity necessary to sustain long-term public health campaigns. A persistent challenge in the region is tobacco industry interference, which necessitates strict adherence to FCTC Article 5.3 to protect public health policies from commercial vested interests. Thailand’s ongoing four-decade confrontation with the tobacco industry and New Zealand’s recent reversal of its ambitious "endgame" legislative package illustrate that even rigorous, evidence-based policies remain politically fragile without durable cross-party consensus and strict firewalls. Furthermore, novel nicotine products, such as e-cigarettes and heated tobacco, are increasingly utilized by the industry to access policymaking processes under the guise of harm reduction. To ensure durable population-level reductions in tobacco use, the following structural features are recommended: (1) Implement the full MPOWER package simultaneously rather than relying on isolated measures. (2) Establish earmarked, transparent financing insulated from annual budget politics. (3) Enact and continuously monitor strict Article 5.3 firewalls across all government branches, including regulations for novel nicotine products. (4) Invest in sustained tobacco industry denormalization (TID) to educate the public and policymakers about industry tactics. (5) Foster regional technical and diplomatic solidarity to support smaller nations in translating FCTC obligations into enforceable laws.

"The tobacco industry acts as the primary ""commercial vector"" driving global non-communicable diseases (NCDs), responsible for approximately 8 million deaths annually and an economic burden of $1.5 trillion. Drawing from clinical and public health evidence presented at APSR 2026, this session examines the multi-faceted tactics employed by tobacco corporations to undermine tobacco control policies, manipulate scientific discourse, and delay life-saving regulations across the Asia-Pacific region. Through a strategic ""policy dystopia"" framework, the industry utilizes discursive narratives—such as warning of economic loss, illicit trade, and legal violations—alongside instrumental strategies, including lobbying non-health government ministries and establishing front groups like ENDS Cigarette Smoke Thailand (ECST). Corporate tactics routinely stall legislation, resulting in years of unenforced acts and policy rollbacks in countries such as Papua New Guinea, Myanmar, Lao PDR, Malaysia, Indonesia, and Thailand. Furthermore, the industry exploits public health crises, such as COVID-19, through corporate social responsibility (CSR) initiatives and tobacco-leaf vaccine research to gain unmonitored access to government officials. To distort scientific reality, the industry promotes ""switch vs. quit"" narratives and funds biased research, with 65% of heated tobacco comparisons being industry-affiliated and 100% of biomarker trials carrying a high risk of bias. Simultaneously, corporations target healthcare professionals through sponsored continuing medical education (CME) and infiltrate the pharmaceutical sector—such as acquiring respiratory inhaler manufacturers—creating a profound ethical conflict by profiting concurrently from tobacco-caused diseases and their treatments. To counter these commercial determinants of health, public health strategies must strictly enforce Article 5.3 of the WHO Framework Convention on Tobacco Control (FCTC) across the whole of government. Comprehensive defense requires enforcing zero-conflict policies, complete transparency, binding codes of conduct, and restricted official interaction. Ultimately, health authorities should adopt the **TARGET** roadmap—focusing on Tobacco endgame, Accelerating MPOWER, Reducing nicotine levels, Generation nicotine-free policies, Eliminating interference, and Tobacco industry denormalization—to isolate the vector and safeguard public health."